AirSculpt Technologies, Inc. (AIRS) 股票分析

公司概述

AirSculpt Technologies, Inc. operates primarily as a holding company overseeing EBS Intermediate Parent LLC, which delivers specialized body contouring procedures to patients in the United States and Canada. Within the broader Healthcare sector, the firm functions specifically within the Medical Care Facilities industry, providing non-invasive fat removal treatments under its proprietary AirSculpt brand. The company maintains a market capitalization of $191.18M and employs approximately 330 individuals to support its operational footprint. While the annual revenue stands at $151.82M, the relatively modest market cap suggests the market values the company at a fraction of its sales volume, indicating a premium on future growth potential or significant concerns regarding current profitability that compresses the valuation multiple relative to its revenue generation scale.

财务健康

The company reported a trailing twelve-month revenue of $151.82M, yet it recorded a net income loss of $11,667,000, while maintaining a positive EBITDA of $7.95M. This substantial divergence between the positive EBITDA and the significant net income loss highlights a cost structure burdened by heavy non-operating expenses, likely interest costs, which erode bottom-line profitability despite healthy core operations. Although the business generates positive free cash flow of $5.17M, the high level of debt limits the extent of this financial flexibility for aggressive expansion or opportunistic acquisitions. The gross margin is robust at 66.0%, indicating efficient direct cost management in service delivery, but this is offset by an operating margin of -4.6% and a profit margin of -7.7%, reflecting the heavy weight of fixed costs or interest obligations. The balance sheet is heavily leveraged with total debt of $83.57M compared to cash reserves of $8.45M, resulting in a debt-to-equity ratio of 95.28, which signifies a high-risk capital structure dependent on continuous cash flow to service obligations. Short-term liquidity is constrained, as evidenced by a current ratio of 0.55, meaning current assets are insufficient to cover current liabilities without asset liquidation. Furthermore, the return on equity is negative at -14.1% and the return on assets is -1.5%, revealing that management has not yet generated returns on capital deployed, a common characteristic in early-stage or restructuring medical facility companies.

估值评估

The trailing twelve-month P/E ratio is N/A due to the negative net income, whereas the forward P/E stands at -90.33, a metric that is difficult to interpret directly but signals that the market expects earnings to improve in the future to justify a positive multiple. The price-to-book ratio is 1.99, suggesting that the market values the company at nearly double its book value, implying investors are pricing in significant future growth or intangible assets not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio of 1.26 and an EV/EBITDA of 33.51 provide context, indicating the company is trading at a premium relative to its sales and earnings power before interest and taxes. The stock's price volatility is evident from a 52-week high of $12.00 and a 52-week low of $1.51, with the current price trading significantly below the yearly peak. A beta of 2.27 indicates that the stock price is highly sensitive to market movements, experiencing approximately 2.27 times the volatility of the broader market index.

Growth & Income

Revenue growth year-over-year has contracted by 14.6%, while earnings growth is N/A due to the lack of comparable positive earnings in the prior period. The contraction in revenue combined with the absence of positive earnings growth implies that the company is currently facing headwinds in patient volume or pricing that have not yet been offset by operational efficiencies. As a non-dividend payer, the company does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash is retained within the business to fund operations and potentially reduce debt. This reinvestment strategy is typical for companies in the medical care facilities sector that prioritize capital allocation toward growth initiatives over income distribution. Consequently, the overall growth and income profile is characterized by negative revenue momentum and a reliance on internal cash generation rather than external capital markets or shareholder distributions to drive value creation.